Seeking Alpha

Astrazeneca's (AZN) naloxegol product for treating opioid-induced constipation (OIC)...

Astrazeneca's (AZN) naloxegol product for treating opioid-induced constipation (OIC) performed well in two Phase III trials and one safety extension study. The trials also brought on no imbalances in serious adverse events. Astrazeneca acquired the worldwide licence for naloxegol from its developer, Nektar Therapeutics (NKTR -0.1%), in 2009. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|